• 2022
  Villares M, Lourenço N, Berthelet J, Lamotte S, Regad L, Medjkane S, Prina E, Rodrigues-Lima F, Späth GF, Weitzman JB, Trifloxystrobin blocks the growth of Theileria parasites and is a promising drug to treat Buparvaquone resistance., Commun Biol 2022 Nov; 5(1): 1253.
• 2020
  Rosazza T, Lecoeur H, Blisnick T, Moya-Nilges M, Pescher P, Bastin P, Prina E, Späth GF, , Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages., J Cell Sci 2020 06; 134(5): .
• 2020
  Baek KH, Piel L, Rosazza T, Prina E, Späth GF, No JH, , Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations., Pathogens 2020 May; 9(5): .
• 2020
  Smirlis D, Dingli F, Pescher P, Prina E, Loew D, Rachidi N, Späth GF, , SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani., J Proteomics 2020 02; 213(): 103617.
• 2020
  Lecoeur H, Prina E, Rosazza T, Kokou K, N'Diaye P, Aulner N, Varet H, Bussotti G, Xing Y, Milon G, Weil R, Meng G, Späth GF, Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response., Cell Rep 2020 Feb; 30(6): 1870-1882.e4.
• 2020
  Lecoeur H, Rosazza T, Kokou K, Varet H, Coppée JY, Lari A, Commère PH, Weil R, Meng G, Milon G, Späth GF, Prina E, , Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation., Front Immunol 2020 ; 11(): 1098.
• 2019
  Lamotte S, Aulner N, Späth GF, Prina E, , Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening., Sci Rep 2019 01; 9(1): 438.
• 2016
  Chua MJ, Arnold MS, Xu W, Lancelot J, Lamotte S, Späth GF, Prina E, Pierce RJ, Fairlie DP, Skinner-Adams TS, Andrews KT, Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth, Int J Parasitol Drugs Drug Resist 2017 04;7(1):42-50.
• 2016
  Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N, Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor, Eur J Med Chem 2017 Jan;125:696-709.
• 2016
  Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N, , From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity., Antimicrob Agents Chemother 2016 05; 60(5): 2822-33.
• 2014
  Forestier CL, Späth GF, Prina E, Dasari S, Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process, Microb. Pathog. 2014 Oct;.
• 2014
  Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, Prina E, Cayla M, Descoteaux A, Späth GF, , Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses., Mol Microbiol 2014 Jul; 93(1): 146-66.
• 2014
  Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF, , Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection., Antimicrob Agents Chemother 2014 ; 58(3): 1501-15.
• 2012
  Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A, , The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms., Structure 2012 Oct; 20(10): 1649-60.